Ironwood amends credit facility to $550M, extends maturity to 2028; declines CNP-104 option

IRONWOOD PHARMACEUTICALS INC

Revolving credit facility increased from $500M to $550M; $400M outstanding as of amendment date.
Maturity extended to earlier of Dec 31, 2028 or 91 days before convertible notes maturity, subject to liquidity.
Maximum consolidated secured net leverage ratio raised to 3.50x (initial period), stepping down to 3.00x; can rise further for acquisitions over $50M.
Ironwood will not exercise option for CNP-104 (primary biliary cholangitis); collaboration with COUR terminates, no further rights or obligations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.